Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JTO.0b013e3181d408bc | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cetuximab-Induced Aseptic Meningitis in a Patient with Colorectal Cancer: A Case Report and Review of Literature.
Case Rep Neurol
November 2022
Department of Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Cetuximab is a chimeric IgG1 monoclonal antibody against epidermal growth factor receptor. It is approved by the European medical agency for the treatment of RAS wild-type metastatic colorectal cancer and metastatic squamous cell cancer of the head and neck. Few cases of aseptic meningitis, primarily associated with the first administration of cetuximab in patients with squamous cell cancer, have been reported.
View Article and Find Full Text PDFA case of aseptic meningitis in a cetuximab-experienced patient with metastatic colon cancer.
J Oncol Pharm Pract
December 2018
2 Cancer Institute of Florida, Orlando, FL, USA.
Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is used in the treatment of head and neck cancer, non-small cell lung cancer, and colorectal cancer. This case report describes a rare (<1% incidence) side effect of cetuximab administration: aseptic meningitis. We report a case which is, to our knowledge, the only case at the time of submission of this manuscript of aseptic meningitis in a patient being treated for metastatic colon cancer who was not cetuximab-naïve.
View Article and Find Full Text PDFCetuximab-induced aseptic meningitis: case report and review of a rare adverse event.
BMC Cancer
July 2016
Department of Oncology, University hospital of Lausanne, Lausanne, Switzerland.
Background: Cetuximab is a commonly used antibody agent in the treatment of colorectal or head and neck cancer. Although it is generally well tolerated in most patients, cetuximab has been associated with some rare but serious adverse events. Aseptic meningitis is one such distinctly uncommon adverse drug reaction.
View Article and Find Full Text PDFMore than a headache: a case of cetuximab-induced aseptic meningitis.
BMJ Case Rep
May 2015
Department of Medicine-Oncology, Jacobi Medical Center, Bronx, New York, USA.
While the wide belief is that monoclonal antibodies, due to their large size, would not be able to penetrate the blood-brain barrier, we present a rare case of aseptic meningitis induced by intravenous cetuximab administration. A 58-year-old man with tonsillar squamous cell cancer presented with headache and fever, which started approximately 1 h after his first dose of cetuximab (loading dose of 400 mg/m(2) equalling 800 mg). CT scan of the head was non-revealing and laboratory tests including complete blood count, serum comprehensive metabolic panel and coagulation profile were within normal limits.
View Article and Find Full Text PDFCetuximab induced aseptic meningitis.
J Clin Neurosci
June 2015
Department of Neurology, University Hospital Zurich, Zurich, Switzerland. Electronic address:
We report a 67-year-old man with recurrent advanced oropharyngeal squamous cell carcinoma who developed aseptic meningitis, with first symptoms arising approximately 9hours after the first administration of cetuximab, and review the literature to identify key signs and symptoms of this condition. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor which has been rarely associated with aseptic meningitis. Besides the case description, a MEDLINE search was performed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!